Click here to get full coverage on Hypertrophic Cardiomyopathy (HCM) - University of Michigan Health

Hypertrophic Cardiomyopathy (HCM)  University of Michigan Health

Hypertrophic Cardiomyopathy (HCM) - University of Michigan Health

Click here to get full coverage on Stress Echo Reveals Hidden Risks in Asymptomatic Hypertrophic Cardiomyopathy - The American Journal of Managed Care® (AJMC®)

Stress Echo Reveals Hidden Risks in Asymptomatic Hypertrophic Cardiomyopathy  The American Journal of Managed Care® (AJMC®)

Stress Echo Reveals Hidden Risks in Asymptomatic Hypertrophic Cardiomyopathy - The American Journal of Managed Care® (AJMC®)

Click here to get full coverage on MAPLE-HCM: Treatment Benefit of Aficamten in Patients With Obstructive HCM - American College of Cardiology

MAPLE-HCM: Treatment Benefit of Aficamten in Patients With Obstructive HCM  American College of Cardiology

MAPLE-HCM: Treatment Benefit of Aficamten in Patients With Obstructive HCM - American College of Cardiology

Click here to get full coverage on Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine - Cytokinetics

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine  Cytokinetics

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine - Cytokinetics

Click here to get full coverage on Expanded effort will help standardize, improve care for hypertrophic cardiomyopathy - www.heart.org

Expanded effort will help standardize, improve care for hypertrophic cardiomyopathy  www.heart.org

Expanded effort will help standardize, improve care for hypertrophic cardiomyopathy - www.heart.org

Click here to get full coverage on MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide - TCTMD.com

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide  TCTMD.com

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide - TCTMD.com

Click here to get full coverage on HCM City Signs a Major Deal with Binance to Strengthen International Financial Centre - CryptoNinjas

HCM City Signs a Major Deal with Binance to Strengthen International Financial Centre  CryptoNinjas

HCM City Signs a Major Deal with Binance to Strengthen International Financial Centre - CryptoNinjas

Click here to get full coverage on Ho Chi Minh to be honored at Montevideo's port - MercoPress

Ho Chi Minh to be honored at Montevideo's port  MercoPress

Ho Chi Minh to be honored at Montevideo's port - MercoPress

Click here to get full coverage on Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - New England Journal of Medicine

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy  New England Journal of Medicine

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - New England Journal of Medicine

Click here to get full coverage on Cardiac myosin inhibitors for the treatment of obstructive and non-obstructive HCM - Nature

Cardiac myosin inhibitors for the treatment of obstructive and non-obstructive HCM  Nature

Cardiac myosin inhibitors for the treatment of obstructive and non-obstructive HCM - Nature

Click here to get full coverage on Myosin Inhibitor for Nonobstructive HCM: No Clinical Benefits but Positive Biomarker and Echo Effects - Cleveland Clinic

Myosin Inhibitor for Nonobstructive HCM: No Clinical Benefits but Positive Biomarker and Echo Effects  Cleveland Clinic

Myosin Inhibitor for Nonobstructive HCM: No Clinical Benefits but Positive Biomarker and Echo Effects - Cleveland Clinic

Click here to get full coverage on Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for 10th Consecutive Year - Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for 10th Consecutive Year  Oracle

Oracle Named a Leader in Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for 10th Consecutive Year - Oracle

Click here to get full coverage on International household goods, gifts expo set to open in HCM City - Vietnam+ (VietnamPlus)

International household goods, gifts expo set to open in HCM City  Vietnam+ (VietnamPlus)

International household goods, gifts expo set to open in HCM City - Vietnam+ (VietnamPlus)

Click here to get full coverage on Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM - Cardiovascular Business

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM  Cardiovascular Business

Hypertrophic Cardiomyopathy Association supports study of potential treatment for nonbstructive HCM - Cardiovascular Business

Click here to get full coverage on Imbria Pharmaceuticals, HCMS Team Up to Support Fortitude-HCM Trial - Diagnostic and Interventional Cardiology

Imbria Pharmaceuticals, HCMS Team Up to Support Fortitude-HCM Trial  Diagnostic and Interventional Cardiology

Imbria Pharmaceuticals, HCMS Team Up to Support Fortitude-HCM Trial - Diagnostic and Interventional Cardiology

Click here to get full coverage on SAP in Gartner Cloud HCM Suites Magic Quadrant - SAP News Center

SAP in Gartner Cloud HCM Suites Magic Quadrant  SAP News Center

SAP in Gartner Cloud HCM Suites Magic Quadrant - SAP News Center

Click here to get full coverage on ODYSSEY-HCM: Mavacamten vs. Placebo in Patients With Symptomatic Nonobstructive HCM - American College of Cardiology

ODYSSEY-HCM: Mavacamten vs. Placebo in Patients With Symptomatic Nonobstructive HCM  American College of Cardiology

ODYSSEY-HCM: Mavacamten vs. Placebo in Patients With Symptomatic Nonobstructive HCM - American College of Cardiology

Click here to get full coverage on Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy - New England Journal of Medicine

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy  New England Journal of Medicine

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy - New England Journal of Medicine

Click here to get full coverage on Asymptomatic Hypertrophic Cardiomyopathy: Insights on Long-Term Outcomes and More - Cleveland Clinic

Asymptomatic Hypertrophic Cardiomyopathy: Insights on Long-Term Outcomes and More  Cleveland Clinic

Asymptomatic Hypertrophic Cardiomyopathy: Insights on Long-Term Outcomes and More - Cleveland Clinic

Click here to get full coverage on A Study of Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy - ODYSSEY-HCM - American College of Cardiology

A Study of Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy - ODYSSEY-HCM  American College of Cardiology

A Study of Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy - ODYSSEY-HCM - American College of Cardiology

Click here to get full coverage on Announcing Oracle’s HCM product priorities - Oracle Blogs

Announcing Oracle’s HCM product priorities  Oracle Blogs

Announcing Oracle’s HCM product priorities - Oracle Blogs

Click here to get full coverage on Voices of HCM: Personal journeys from across the globe - Bristol Myers Squibb

Voices of HCM: Personal journeys from across the globe  Bristol Myers Squibb

Voices of HCM: Personal journeys from across the globe - Bristol Myers Squibb

Click here to get full coverage on Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants | Circulation - American Heart Association Journals

Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants | Circulation  American Heart Association Journals

Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate-Effect Variants | Circulation - American Heart Association Journals

Click here to get full coverage on Habits to Improve Your Health When Living with HCM - HealthCentral

Habits to Improve Your Health When Living with HCM  HealthCentral

Habits to Improve Your Health When Living with HCM - HealthCentral

Click here to get full coverage on 96-Week FOREST-HCM Data Support Aficamten Use in Nonobstructive HCM - HCPLive

96-Week FOREST-HCM Data Support Aficamten Use in Nonobstructive HCM  HCPLive

96-Week FOREST-HCM Data Support Aficamten Use in Nonobstructive HCM - HCPLive

Click here to get full coverage on Discover the Power of PeopleSoft HCM Image 52 - Oracle Blogs

Discover the Power of PeopleSoft HCM Image 52  Oracle Blogs

Discover the Power of PeopleSoft HCM Image 52 - Oracle Blogs

Click here to get full coverage on New Insights About the Effects of Valsartan on Early-Stage Hypertrophic Cardiomyopathy - Cleveland Clinic

New Insights About the Effects of Valsartan on Early-Stage Hypertrophic Cardiomyopathy  Cleveland Clinic

New Insights About the Effects of Valsartan on Early-Stage Hypertrophic Cardiomyopathy - Cleveland Clinic

Click here to get full coverage on 12 Important HCM Vendor Questions to Ask Before You Buy - HRMorning

12 Important HCM Vendor Questions to Ask Before You Buy  HRMorning

12 Important HCM Vendor Questions to Ask Before You Buy - HRMorning

Click here to get full coverage on ESC25: Cytokinetics says new aficamten data may upend HCM treatment norms - FirstWord Pharma

ESC25: Cytokinetics says new aficamten data may upend HCM treatment norms  FirstWord Pharma

ESC25: Cytokinetics says new aficamten data may upend HCM treatment norms - FirstWord Pharma

Click here to get full coverage on A Look at Recent Updates to Salary Basis in Fusion HCM Analytics - Oracle Blogs

A Look at Recent Updates to Salary Basis in Fusion HCM Analytics  Oracle Blogs

A Look at Recent Updates to Salary Basis in Fusion HCM Analytics - Oracle Blogs

Click here to get full coverage on HCM City celebrates 65 years of Vietnam-Cuba diplomatic relations - Vietnam+ (VietnamPlus)

HCM City celebrates 65 years of Vietnam-Cuba diplomatic relations  Vietnam+ (VietnamPlus)

HCM City celebrates 65 years of Vietnam-Cuba diplomatic relations - Vietnam+ (VietnamPlus)

Click here to get full coverage on Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy - University of Utah Health

Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy  University of Utah Health

Managing the Most Common Inherited Disease of the Heart Muscle: Hypertrophic Cardiomyopathy - University of Utah Health

Click here to get full coverage on Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy - Nature

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy  Nature

Multimodal AI to forecast arrhythmic death in hypertrophic cardiomyopathy - Nature

Click here to get full coverage on 25D roadmaps—new agents for ERP, HCM, SCM, CX - Oracle Blogs

25D roadmaps—new agents for ERP, HCM, SCM, CX  Oracle Blogs

25D roadmaps—new agents for ERP, HCM, SCM, CX - Oracle Blogs

Click here to get full coverage on Cytokinetics Presents Additional Data from MAPLE-HCM at the - GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the  GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the - GlobeNewswire

Click here to get full coverage on Mavacamten does not improve outcomes in nonobstructive HCM - Healio

Mavacamten does not improve outcomes in nonobstructive HCM  Healio

Mavacamten does not improve outcomes in nonobstructive HCM - Healio

Click here to get full coverage on HCM City gathering marks Thailand’s 98th National Day, cements bilateral bonds - Vietnam+ (VietnamPlus)

HCM City gathering marks Thailand’s 98th National Day, cements bilateral bonds  Vietnam+ (VietnamPlus)

HCM City gathering marks Thailand’s 98th National Day, cements bilateral bonds - Vietnam+ (VietnamPlus)

Click here to get full coverage on MAPLE-HCM: Aficamten Proves Superiority to Metoprolol in Hypertrophic Cardiomyopathy - HCPLive

MAPLE-HCM: Aficamten Proves Superiority to Metoprolol in Hypertrophic Cardiomyopathy  HCPLive

MAPLE-HCM: Aficamten Proves Superiority to Metoprolol in Hypertrophic Cardiomyopathy - HCPLive

Click here to get full coverage on Can You Exercise With Hypertrophic Cardiomyopathy? - Cleveland Clinic Health Essentials

Can You Exercise With Hypertrophic Cardiomyopathy?  Cleveland Clinic Health Essentials

Can You Exercise With Hypertrophic Cardiomyopathy? - Cleveland Clinic Health Essentials

Click here to get full coverage on Are South Indians at higher risk of heart disease? New inStem study reveals unique genetic signature - livemint.com

Are South Indians at higher risk of heart disease? New inStem study reveals unique genetic signature  livemint.com

Are South Indians at higher risk of heart disease? New inStem study reveals unique genetic signature - livemint.com

Click here to get full coverage on Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM  TCTMD.com

Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM - TCTMD.com

Click here to get full coverage on Hypertrophic cardiomyopathy - Nature

Hypertrophic cardiomyopathy - Nature

Click here to get full coverage on Exercising With Hypertrophic Cardiomyopathy (HCM): What You Need to Know - Everyday Health

Exercising With Hypertrophic Cardiomyopathy (HCM): What You Need to Know  Everyday Health

Exercising With Hypertrophic Cardiomyopathy (HCM): What You Need to Know - Everyday Health

Click here to get full coverage on Trials Expand Evidence for Hypertrophic Cardiomyopathy Tx - Medscape

Trials Expand Evidence for Hypertrophic Cardiomyopathy Tx  Medscape

Trials Expand Evidence for Hypertrophic Cardiomyopathy Tx - Medscape

Click here to get full coverage on Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis - American Heart Association Journals

Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis  American Heart Association Journals

Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis - American Heart Association Journals

Click here to get full coverage on Hypertrophic Cardiomyopathy - New England Journal of Medicine

Hypertrophic Cardiomyopathy  New England Journal of Medicine

Hypertrophic Cardiomyopathy - New England Journal of Medicine

Click here to get full coverage on Rapamycin therapy for subclinical HCM in cats is now available through telemedicine - DVM360

Rapamycin therapy for subclinical HCM in cats is now available through telemedicine  DVM360

Rapamycin therapy for subclinical HCM in cats is now available through telemedicine - DVM360

Click here to get full coverage on 10 Top Centers for Hypertrophic Cardiomyopathy Care in the U.S. - HealthCentral

10 Top Centers for Hypertrophic Cardiomyopathy Care in the U.S.  HealthCentral

10 Top Centers for Hypertrophic Cardiomyopathy Care in the U.S. - HealthCentral

Click here to get full coverage on HCM II Acquisition Corp. Shareholders Approve Business Combination with Terrestrial Energy - Yahoo Finance

HCM II Acquisition Corp. Shareholders Approve Business Combination with Terrestrial Energy  Yahoo Finance

HCM II Acquisition Corp. Shareholders Approve Business Combination with Terrestrial Energy - Yahoo Finance

Click here to get full coverage on MAPLE-HCM: CPET Data Support Aficamten over Metoprolol as Monotherapy - HCPLive

MAPLE-HCM: CPET Data Support Aficamten over Metoprolol as Monotherapy  HCPLive

MAPLE-HCM: CPET Data Support Aficamten over Metoprolol as Monotherapy - HCPLive

Click here to get full coverage on Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM - HCPLive

Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM  HCPLive

Mavacamten Falls Short in Phase 3 Trial for Non-Obstructive HCM - HCPLive

Click here to get full coverage on Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)  PR Newswire

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - PR Newswire

Click here to get full coverage on Aficamten Updates in Two Hypertrophic Cardiomyopathy Trials - Medscape

Aficamten Updates in Two Hypertrophic Cardiomyopathy Trials  Medscape

Aficamten Updates in Two Hypertrophic Cardiomyopathy Trials - Medscape

Click here to get full coverage on Intelligent HCM Software - Paycor

Intelligent HCM Software - Paycor

Click here to get full coverage on Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025  Clinical Trials Arena

Tenaya highlights HCM gene therapy interim data at ACC 2025 - Clinical Trials Arena

Click here to get full coverage on Epistasis regulates genetic control of cardiac hypertrophy - Nature

Epistasis regulates genetic control of cardiac hypertrophy  Nature

Epistasis regulates genetic control of cardiac hypertrophy - Nature

Click here to get full coverage on South or North Indians? Bengaluru research reveals which group is more at risk of heart diseases | Health - Hindustan Times

South or North Indians? Bengaluru research reveals which group is more at risk of heart diseases | Health  Hindustan Times

South or North Indians? Bengaluru research reveals which group is more at risk of heart diseases | Health - Hindustan Times

Click here to get full coverage on Mavacamten No Match for Nonobstructive HCM in Phase III Trial - MedPage Today

Mavacamten No Match for Nonobstructive HCM in Phase III Trial  MedPage Today

Mavacamten No Match for Nonobstructive HCM in Phase III Trial - MedPage Today

Click here to get full coverage on Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results  FirstWord Pharma

Safety signals overshadow Edgewise's HCM drug trial results - FirstWord Pharma

Click here to get full coverage on Paychex Honored as an HCM Technology and GenAI Leader - Business Wire

Paychex Honored as an HCM Technology and GenAI Leader  Business Wire

Paychex Honored as an HCM Technology and GenAI Leader - Business Wire

Click here to get full coverage on BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial  FirstWord Pharma

BMS's Camzyos falls short in Phase III non-obstructive HCM trial - FirstWord Pharma

Click here to get full coverage on Human Capital Management - CBIZ

Human Capital Management - CBIZ

Click here to get full coverage on ​​​​​​​HCM City streamlines regulations to stimulate industrial park growth - vietnamnews.vn

​​​​​​​HCM City streamlines regulations to stimulate industrial park growth  vietnamnews.vn

​​​​​​​HCM City streamlines regulations to stimulate industrial park growth - vietnamnews.vn

Click here to get full coverage on Hot Line 2: ODYSSEY-HCM - European Society of Cardiology

Hot Line 2: ODYSSEY-HCM  European Society of Cardiology

Hot Line 2: ODYSSEY-HCM - European Society of Cardiology

Click here to get full coverage on Patient story: Forty years searching for answers — Alphonse’s HCM journey - Bristol Myers Squibb

Patient story: Forty years searching for answers — Alphonse’s HCM journey  Bristol Myers Squibb

Patient story: Forty years searching for answers — Alphonse’s HCM journey - Bristol Myers Squibb

Click here to get full coverage on Hot Line 2: MAPLE-HCM - European Society of Cardiology

Hot Line 2: MAPLE-HCM  European Society of Cardiology

Hot Line 2: MAPLE-HCM - European Society of Cardiology

Click here to get full coverage on Forrester Named ADP a Leader in HCM Wave 2025 Evaluation - ADP

Forrester Named ADP a Leader in HCM Wave 2025 Evaluation  ADP

Forrester Named ADP a Leader in HCM Wave 2025 Evaluation - ADP

Click here to get full coverage on COLLIGO-HCM: Mavacamten (CAMZYOS) Effective in Obstructive HCM With Pankaj Arora, MD - HCPLive

COLLIGO-HCM: Mavacamten (CAMZYOS) Effective in Obstructive HCM With Pankaj Arora, MD  HCPLive

HCM

Price Chart

Key Statistics

Technicals

About HCM

Latest News

Hypertrophic Cardiomyopathy (HCM) - University of Michigan Health

Stress Echo Reveals Hidden Risks in Asymptomatic Hypertrophic Cardiomyopathy - The American Journal of Managed Care® (AJMC®)

MAPLE-HCM: Treatment Benefit of Aficamten in Patients With Obstructive HCM - American College of Cardiology

Advanced Charts

Top Gainers

Top Losers